Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21776538 | 0.87 | MAPK1 (0.50) | LMNAKDM4ENOTUMMEN1KMT2A | |
| SCHEMBL679402 | 0.86 | KDM4E (0.57) | LMNAKDM4ENOTUMMEN1KMT2A | |
| SCHEMBL21786022 | 0.85 | ALDH1A1 (0.52) | LMNAKDM4ENOTUMPOLBALDH1A1 | |
| SCHEMBL30208868 | 0.85 | ALDH1A1 (0.52) | LMNAKDM4ENOTUMPOLBALDH1A1 | |
| SCHEMBL21786023 | 0.84 | NOTUM (0.57) | LMNAKDM4ENOTUMKMT2AL3MBTL1 | |
| SCHEMBL30209010 | 0.84 | NOTUM (0.57) | LMNAKDM4ENOTUMKMT2AL3MBTL1 | |
| SCHEMBL23147088 | 0.82 | LMNA (0.55) | LMNAKDM4ENOTUMMEN1KMT2A | |
| SCHEMBL26756327 | 0.82 | KDM4E (0.45) | LMNAKDM4ENOTUMMEN1KMT2A | |
| SCHEMBL680604 | 0.82 | ALDH1A1 (0.52) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL21383288 | 0.82 | MAPK1 (0.58) | LMNAKDM4ENOTUMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-3762392-B1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO LTD (KR) | 2024-05-15 | — | — | EP | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11447500-B2 | Thienopyridine derivatives and pharmaceutical composition comprising same | WELLMARKER BIO CO., LTD. (KR) | 2022-09-20 | — | — | US | disclosed |
| WO-2019182274-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2019-09-26 | — | — | WO | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8445509-B2 | Fused heterocyclic derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| CN-102105462-A | Amidophenoxyindazoles useful as inhibitors of C-MET | LILLY CO ELI | 2011-06-22 | — | — | CN | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447500-B2 | Thienopyridine derivatives and pharmaceutical composition comprising same | MAP4K5, MAP4K2, MAP3K9 | LMNA 4196/4885KDM4E 2286/4885NOTUM 2383/4885 |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | LMNA 3554/4885KDM4E 935/4885NOTUM 4690/4885 |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | LMNA 3447/4885KDM4E 951/4885NOTUM 4687/4885 |
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | LMNA 3734/4885KDM4E 947/4885NOTUM 1749/4885 |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | RET, MERTK, MET | LMNA 3554/4885KDM4E 935/4885NOTUM 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.